Literature DB >> 29374726

Clinical Assessment of Micro-residual Tumors during Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.

Kenji Uemoto1,2, Hiroshi Doi3,4, Hiroya Shiomi3, Koichi Yamada3, Daisaku Tatsumi3, Taku Yasumoto3, Masaaki Takashina5, Masahiko Koizumi2, Ryoong-Jin Oh3.   

Abstract

BACKGROUND: This study aimed to assess the need to consider microscopic invasion in terms of treatment planning in stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma and elucidate the appropriate clinical target volume (CTV) margin. PATIENTS AND METHODS: A total of 121 patients (with 146 liver tumors) who underwent SBRT between July 2007 and August 2016 were analyzed, regarding overall survival and local control (LC).
RESULTS: The 2- and 5-year LC rates were 91.5% and 89.8%, respectively. Planning target volume (PTV) margin <8 mm was associated with poor LC. Of the 77 patients with PTV margin of <8 mm, age <75 years was associated with poor LC, while alpha-fetoprotein (AFP) ≤20 ng/ml was associated with good LC.
CONCLUSION: In patients with high AFP levels, there is a possibility of microscopic invasion around the tumor, suggesting that LC may be improved by adding an additional clinical target volume margin to the gross tumor volume. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Stereotactic body radiation therapy; hepatocellular carcinoma; intensity-modulated radiotherapy; stereotactic ablative radiation therapy

Mesh:

Substances:

Year:  2018        PMID: 29374726     DOI: 10.21873/anticanres.12308

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Escalated Maximum Dose in the Planning Target Volume Improves Local Control in Stereotactic Body Radiation Therapy for T1-2 Lung Cancer.

Authors:  Takaya Inagaki; Hiroshi Doi; Naoko Ishida; Aritoshi Ri; Saori Tatsuno; Yutaro Wada; Takuya Uehara; Masahiro Inada; Kiyoshi Nakamatsu; Makoto Hosono; Yasumasa Nishimura
Journal:  Cancers (Basel)       Date:  2022-02-13       Impact factor: 6.639

2.  PIVKA-II as a surrogate marker for prognosis in patients with localized hepatocellular carcinoma receiving stereotactic body radiotherapy.

Authors:  Ick Joon Cho; Jae-Uk Jeong; Taek-Keun Nam; Young-Eun Joo; Sung-Bum Cho; Yong-Hyub Kim; Ju-Young Song; Mee Sun Yoon; Sung-Ja Ahn; Woong-Ki Chung
Journal:  Radiat Oncol J       Date:  2022-03-25

3.  Screening of Prognostic Biomarkers for Stereotactic Body Radiation Therapy in Primary Liver Cancer.

Authors:  Zhenzhen Liang; Chang Xue; Qing Chen; Mengke Li; Guanghui Li; Hao Feng; Yi Liu; Xiaodong Liu; Shumei Ma
Journal:  Dose Response       Date:  2022-05-06       Impact factor: 2.623

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.